Patients exposed to rabies, who had a history of having received a complete series of intramuscular or intradermal postexposure vaccine treatment 5 or more years previously, all developed an early anamnestic antibody response to two intradermal booster vaccine injections. It is suggested that such subjects do not require a full five-dose postexposure series nor do they require administration of rabies immune globulin. These data confirm World Health Organization and US-CDC recommendations.
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Current World Health Organization (WHO) recommendations state that indi&duals,previously vaccinated against rabies with a potent tissue or avian culture vaccine, should be given two tissue or avian culture vaccine boosters on days 0 and 3 ifpostexposure vaccination is required. Boosters can be ahnistered either intramuscularly as a full ampoule or i n t r a d e r d y as 0.1 mL if the ampoule is reconstituted in 0.5 mL solution or 0.2 mL. if the diluent provided with the vaccine is 1 .O mL.'** Previous studies supported this recommendation.' Investigators at this institution published a study of nerve tissue-derived vaccine recipients, reexposed to rabies up to 50 years after their original immunization, and found that most but not all had an accelerated immune response and thus showed immunological memory. This was not related to the time elapsed since the previous Semple or suckling mouse brain va~cination.~ A recent simulated postexposure booster study in Thai veterinary and nursing students, who had the preexposure vaccination by the intramuscular or intradermal route, demonstrated acceierated antibody formation when given two intradermal or inmmuscular boosters 1 year later5 Subjects in the intradermal group, however, had significantly lower antibody titers than those in the intramuscular group.' This institution treats approximately 80 rabies exposed patients every month who have had prior tissue culture rabies vaccination. Due to financial constraints, the reduced-dose intradermal mute is used whenever possible.* Our clinic staff and the patients are then often fearful when only two boosters are given to previously vaccinated and new rabies exposed subjects; and that without immune globulin injected in and around bite wounds.'V2 This concern led us to carry out this prospective study on severely rabies reexposed subjects who had prior tissue culture postexposure rabies vaccination more than 5 years before the new exposure.
Methods
We recruited patients with possible or proven rabies exposure who had a documented history of rabies postexposure vaccination (PET) with or without immune globulin more than 5 years previously. A history of tissue culture vaccines such as human diploid cell (HDCV), purified Vero cell (PVRV), purified duck embryo cell (PDEV) or purified chick embryo cell (PCEC) product was acceptable. The patients were then treated according to current WHO recommendations'*2 by wound cleansing, antisepsis and intradermal administration of PDEV (Swiss Serum and Vaccine Institute, Bern, batch 13 8220123, potency 6.9 IU/mL). Patients received the PDEV as 0.2 mL. b m the 1 .O mL reconstituted ampoule intradermally into the deltoid region on days 0 and 3. Neutralizing antibody determination was carried out at our immunology laboratory using the method of J. S . Smith.b The study was reviewed and approved by the Ethics Committee of the Thai Red Cross Institute. The hnding sources had no role in gathering, analyzing or interpreting the data or in the decision to submit this paper for publication. '
Results
A total of 57 patients were recruited for the study in 1996 and 1997. Only 38 subjects returned for blood collection after receiving the boosters of 0.2 mL. PDEV intradermally on days 0 and 3. The remaining 20 patients provided us with a serum sample on day 0 but did not give us further blood samples. Table I and Figure I demonstrate the neutralizing antibody titers of patients with previous postexposure vaccination and includes the subjects where serum was only available on day 0 before boosters were given. Thirty-one patients had their previous PET using the conventional five dose intramuscular (Essen) Schedule, the other 26 received the Thai Red Cross intradermal regimen.',' HDCV had been used in I1 patients, PVRV in 43 and PCEC in 4 cases.
All patients had detectable antibody titers before boosters on day 0 which were above 0.5 IU/mL in 77% of the cases. There was no statistical difference between recipients of the different vaccines. All had an accelerated immune response with neutralizing titers well over 0.5 I U / d (the WHO recommended minimum acceptable level) on day 7 as well as high titers on day 14. Four of 18 subjects who gave us serum on day 3 post booster had titers over 0.5 I U / d . Subjects who had received the complete Thai Red Cross intradermal postexposure regimen previously which, unlike the other two WHO approved PET schedules includes a booster dose on day 90, had a significantly higher (p < .05) geometric mean titer (GMT) on day 0 and 7 than those that had received the intramuscular Essen schedule.'.' GMTs were significantly higher in all of the study subjects when compared to our previous study of nerve tissue derived vaccine recipients.' There was no significant difference between the group of patients who had received previous vaccination 5-10 years earlier (GMT 0.84, 0.80, 6.59, 14.35 IU/mL. on days 0,3,7 and 14) from those who had PET I 0 years or more previously (GMT 0.55, 0.69, 4.60, 20 .24 I U / d on days 0,3,7 and 14). Adverse side effects &om the m o booster injections were minor. They were equivalent to what we had seen in a previous study of PDEV' N o serum sickness-like reactions were seen as have been reported with booster rabies vaccination using HDCV8 None of the patients have died of rabies during the following year.
Discussion
The number of patients studied is s m d and h s study will be continued. However, when these data are seen in the context of previous reports of tissue and avian culture vaccine immune response e n d~r a n c e ,~ they confirm that they elicit long lasting immune memory. Previous complete series postexposure tissue or avian culture vaccine recipients, who experience a rabies reexposure, can be expected to produce an early accelerated neutralizing antibody response with the currently recommended two booster injections. 
